Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Publishing; 2013.
   Google Scholar
• McConaughy SH, Volpe RJ, Antshel KM, et al. Academic and social impairments associated with attention deficit/hyperactivity disorder. School Psych Rev. 2011;40(2):200–225. doi: 10.1080/02796015.2011.12087713
   Web of Science ®Google Scholar
• DuPaul GJ, Morgan PL, Farkas G, et al. Academic and social functioning associated with attention-deficit/hyperactivity disorder: latent class analyses of trajectories from kindergarten to fifth grade. J Abnorm Child Psychol. 2016;44(7):1425–1438. doi: 10.1007/s10802-016-0126-z
   PubMed Web of Science ®Google Scholar
• Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.
   PubMed Web of Science ®Google Scholar
• Li Y, Yan X, Li Q, et al. Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017-2022. JAMA Netw Open. 2023;6(10):e2336872. doi: 10.1001/jamanetworkopen.2023.36872
   PubMed Web of Science ®Google Scholar
• Caye A, Spadini AV, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25(11):1151–1159. doi: 10.1007/s00787-016-0831-8
   PubMed Web of Science ®Google Scholar
• Sibley MH, Swanson JM, Arnold LE, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatr. 2017;58(6):655–662. doi: 10.1111/jcpp.12620
   PubMed Web of Science ®Google Scholar
• Sibley MH, Arnold LE, Swanson JM, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142–151. doi: 10.1176/appi.ajp.2021.21010032
   PubMed Web of Science ®Google Scholar
• Nazarova VA, Sokolov AV, Chubarev VN, et al. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022;13:1066988. doi: 10.3389/fphar.2022.1066988
   PubMed Web of Science ®Google Scholar
• Del Campo N, Chamberlain SR, Sahakian BJ, et al. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145–e157. doi: 10.1016/j.biopsych.2011.02.036
   PubMed Web of Science ®Google Scholar
• Quintero J, Guiterrez-Casares JR, Alamo C. Molecular characterisation of the mechanism of action of stimulant drugs lisdexamfetamine and methylphenidate on ADHD neurobiology: a review. Neurol Ther. 2022;11(4):1489–1517. doi: 10.1007/s40120-022-00392-2
   PubMed Web of Science ®Google Scholar
• Wang LJ, Yu YH, Fu ML, et al. Attention deficit-hyperactivity disorder is associated with allergic symptoms and low levels of hemoglobin and serotonin. Sci Rep. 2018;8(1):10229. doi: 10.1038/s41598-018-28702-5
   PubMedGoogle Scholar
• Sheehan K, Lowe N, Kirley A, et al. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry. 2005;10(10):944–949. doi: 10.1038/sj.mp.4001698
   PubMed Web of Science ®Google Scholar
• Walitza S, Renner TJ, Dempfle A, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry. 2005;10(12):1126–1132. doi: 10.1038/sj.mp.4001734
   PubMed Web of Science ®Google Scholar
• Zoroglu SS, Erdal ME, Alasehirli B, et al. Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem repeat polymorphism in attention deficit hyperactivity disorder. Neuropsychobiology. 2002;45(4):176–181. doi: 10.1159/000063667
   PubMed Web of Science ®Google Scholar
• Hawi Z, Dring M, Kirley A, et al. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry. 2002;7(7):718–725. doi: 10.1038/sj.mp.4001048
   PubMed Web of Science ®Google Scholar
• Quist JF, Barr CL, Schachar R, et al. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol Psychiatry. 2000;5(5):537–541. doi: 10.1038/sj.mp.4000779
   PubMed Web of Science ®Google Scholar
• Quist JF, Barr CL, Schachar R, et al. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Mol Psychiatry. 2003;8(1):98–102. doi: 10.1038/sj.mp.4001244
   PubMed Web of Science ®Google Scholar
• Ribases M, Ramos-Quiroga JA, Hervas A, et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry. 2009;14(1):71–85. doi: 10.1038/sj.mp.4002100
   PubMed Web of Science ®Google Scholar
• Xu X, Brookes K, Sun B, et al. Investigation of the serotonin 2C receptor gene in attention deficit hyperactivity disorder in UK samples. BMC Res Notes. 2009;2(1):71. doi: 10.1186/1756-0500-2-71
   PubMedGoogle Scholar
• Maltezos S, Horder J, Coghlan S, et al. Glutamate/Glutamine and neuronal integrity in adults with ADHD: a proton MRS study. Transl Psychiatry. 2014;4(3):e373. doi: 10.1038/tp.2014.11
   PubMedGoogle Scholar
• Mamiya PC, Richards TL, Edden RAE, et al. Reduced glx and GABA inductions in the anterior cingulate cortex and caudate nucleus are related to impaired control of attention in attention-deficit/hyperactivity disorder. Int J Mol Sci. 2022;23(9):4677. doi: 10.3390/ijms23094677
   PubMed Web of Science ®Google Scholar
• da Silva BS, Grevet EH, Silva L, et al. An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder. Discover Mental Health. 2023;3(2). doi: 10.1007/s44192-022-00030-1
   PubMedGoogle Scholar
• Wolraich ML, Hagan JFJ, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4). doi: 10.1542/peds.2019-2528
   Web of Science ®Google Scholar
• Mechler K, Banaschewski T, Hohmann S, et al. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2022;230:107940. doi: 10.1016/j.pharmthera.2021.107940
   PubMed Web of Science ®Google Scholar
• Antshel KM, Hargrave TM, Simonescu M, et al. Advances in understanding and treating ADHD. BMC Med. 2011;9(1):72. doi: 10.1186/1741-7015-9-72
   PubMedGoogle Scholar
• Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192–206. doi: 10.5863/1551-6776-21.3.192
   PubMedGoogle Scholar
• Elliott J, Johnston A, Husereau D, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. PLoS One. 2020;15(10):e0240584. doi: 10.1371/journal.pone.0240584
   PubMed Web of Science ®Google Scholar
• Shier AC, Reichenbacher T, Ghuman HS, et al. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2013;5:1–17. doi: 10.4137/JCNSD.S6691
   PubMedGoogle Scholar
• Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450–462. doi: 10.1016/S0140-6736(19)33004-1
   PubMed Web of Science ®Google Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270. doi: 10.1016/j.neubiorev.2018.02.001
   PubMed Web of Science ®Google Scholar
• Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68(9):854–860. doi: 10.1016/j.biopsych.2010.06.017
   PubMed Web of Science ®Google Scholar
• Birn RM, Converse AK, Rajala AZ, et al. Changes in endogenous dopamine induced by methylphenidate predict functional connectivity in nonhuman primates. J Neurosci. 2019;39(8):1436–1444. doi: 10.1523/JNEUROSCI.2513-18.2018
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121. doi: 10.1523/JNEUROSCI.21-02-j0001.2001
   PubMed Web of Science ®Google Scholar
• Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6(1):6. doi: 10.1186/1471-2210-6-6
   PubMedGoogle Scholar
• Teixeira-Gomes A, Costa VM, Feio-Azevedo R, et al. The neurotoxicity of amphetamines during the adolescent period. Int J Dev Neurosci. 2015;41(1):44–62. doi: 10.1016/j.ijdevneu.2014.12.001
   PubMedGoogle Scholar
• Underhill SM, Hullihen PD, Chen J, et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha(13) and Galpha(S) in discrete subcellular domains. Mol Psychiatry. 2021;26(4):1208–1223. doi: 10.1038/s41380-019-0469-2
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Mattingly GW, Jain R, et al. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2022;27(2):199–207. doi: 10.1017/S1092852920001984
   PubMed Web of Science ®Google Scholar
• Stevens JR, Wilens TE, Stern TA. Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord. 2013;15(2). doi: 10.4088/PCC.12f01472
   PubMedGoogle Scholar
• US department of justice drug enforcement administration - controlled substance schedules. [cited 2023 Mar 10]. Available from: https://www.deadiversion.usdoj.gov/schedules/
   Google Scholar
• US Food & Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. 2023 [cited 2023 Sep 21]. Available from: https://www.fda.gov/media/168066/download?attachment
   Google Scholar
• US Food & Drug Administration. FDA requires updates to clarify labeling of prescription stimulants used to treat ADHD and other conditions. 2023 [cited 2023 Oct 26]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-updates-clarify-labeling-prescription-stimulants-used-treat-adhd-and-other-conditions
   Google Scholar
• Strattera. Prescribing information. Eli Lilly; 2022 [cited 2023 Jul 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021411s050lbl.pdf
   Google Scholar
• Kapvay. Prescribing information. Concordia Pharmaceuticals; 2020 [cited 2023 Sep 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf)
   Google Scholar
• Intuniv. Prescribing information. Shire; 2019 [cited 2024 Feb 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
   Google Scholar
• Robbins TW. Pharmacological treatment of cognitive deficits in nondementing mental health disorders. Dialogues Clin Neurosci. 2019;21(3):301–308. doi: 10.31887/DCNS.2019.21.3/trobbins
   PubMed Web of Science ®Google Scholar
• Dickson RA, Maki E, Gibbins C, et al. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatr Ment Health. 2011;5(1):14. doi: 10.1186/1753-2000-5-14
   PubMedGoogle Scholar
• Qelbree. Prescribing information. Supernus Pharmaceuticals, Inc.; 2022 [cited 2023 Feb 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf
   Google Scholar
• Chen YL, Skende E, Lin J, et al. Absorption, distribution, metabolism, and excretion of [(14)C]-dasotraline in humans. Pharmacol Res Perspect. 2017;5(1):e00281. doi: 10.1002/prp2.281
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Sunkaraneni S, Skende E, et al. Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. Clin Drug Investig. 2016;36(2):137–146. doi: 10.1007/s40261-015-0358-7
   PubMed Web of Science ®Google Scholar
• Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015;40(12):2745–2752. doi: 10.1038/npp.2015.124
   PubMed Web of Science ®Google Scholar
• Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019;29(2):80–89. doi: 10.1089/cap.2018.0083
   PubMed Web of Science ®Google Scholar
• Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and safety of dasotraline in children with ADHD: a laboratory classroom study. J Atten Disord. 2020;24(2):192–204. doi: 10.1177/1087054719864644
   PubMed Web of Science ®Google Scholar
• Adler LA, Goldman R, Hopkins SC, et al. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. Int Clin Psychopharmacol. 2021;36(3):117–125. doi: 10.1097/YIC.0000000000000333
   PubMed Web of Science ®Google Scholar
• FDA issues a complete response letter for new drug application for dasotraline for the treatment of ADHD. News release. Sunovion Press Release. 2018 Aug 31 [cited 2023 Sep 19]. Available from: https://news.sunovion.com/press-releases/press-releases-details/2018/FDA-Issues-a-Complete-Response-Letter-for-New-Drug-Application-for-Dasotraline-for-the-Treatment-of-ADHD/default.aspx
   Google Scholar
• Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. The Synapse. 2012;66(6):522–532. doi: 10.1002/syn.21538
   PubMed Web of Science ®Google Scholar
• Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42(5):429–439. doi: 10.1097/JCP.0000000000001575
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal T, Hobart M, et al. Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies. Neuropsychiatr Dis Treat. 2020;16:1411–1426. doi: 10.2147/NDT.S242084
   PubMed Web of Science ®Google Scholar
• A trial of centanafadine long-term safety in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). ClinicalTrials.Gov identifier: NCT05279313. 2023 Apr 12 [cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT05279313.)
   Google Scholar
• Konofal E, Zhao W, Laouenan C, et al. Pilot phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014;8:2321–2332. doi: 10.2147/DDDT.S65495
   PubMedGoogle Scholar
• Houlihan WJ, Kelly L, Pankuch J, et al. Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002;45(19):4097–4109. doi: 10.1021/jm010302r
   PubMed Web of Science ®Google Scholar
• Wigal TL, Newcorn JH, Handal N, et al. A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). CNS Drugs. 2018;32(3):289–301. doi: 10.1007/s40263-018-0503-y
   PubMed Web of Science ®Google Scholar
• Sunosi. Prescribing information. Jazz Pharmaceuticals; 2019 [cited 2023 Mar 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
   Google Scholar
• Naguy A, El-Sheshaie A, Elsori DH, et al. Solriamfetol for attention deficit hyperactivity disorder. CNS Spectr. 2022;27(6):662–663. doi: 10.1017/S1092852921000328
   PubMed Web of Science ®Google Scholar
• A controlled study of solriamfetol for ADHD in adults. ClinicalTrials.gov identifier: NCT04839562. 2023 Mar 23 [cited 2023 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04839562
   Google Scholar
• Surman CBH, Walsh DM, Horick N, et al. Solriamfetol for attention-deficit/hyperactivity disorder in adults: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2023;84(6). doi: 10.4088/JCP.23m14934
   PubMed Web of Science ®Google Scholar
• Mallion KB, Todd AH, Turner RW, et al. 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent. Nature. 1972;238(5360):157–158. doi: 10.1038/238157a0
   PubMed Web of Science ®Google Scholar
• Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–653. doi: 10.1007/s40263-021-00825-w
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Orphan Drug Designations and approvals [cited 2023 Feb 23]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=2384
   Google Scholar
• Bayliss PFC, Harcup JW, Mayer M, et al. An open study of two dose levels of ‘vivalan’ (viloxazine hydrochloride ICI 58 834) in depression in general practice. J Int Med Res. 1974;2(4):260–264. doi: 10.1177/030006057400200402
   Web of Science ®Google Scholar
• Altamura AC, Mauri MC, Girardi T, et al. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10(5):293–298.
   PubMedGoogle Scholar
• Meldrum BS, Anlezark GM, Adam HK, et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacol (Berl). 1982;76(3):212–217. doi: 10.1007/BF00432547
   PubMed Web of Science ®Google Scholar
• Blackburn TP, Foster GA, Greenwood DT, et al. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52(3–4):367–374. doi: 10.1016/0014-2999(78)90291-1
   PubMed Web of Science ®Google Scholar
• Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17(6):421–423. doi: 10.1016/0028-3908(78)90018-7
   PubMed Web of Science ®Google Scholar
• Garcia-Olivares J, Yegla B, Bymaster FP, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and Serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-Deficit/Hyperactivity disorder. J Exp Pharmacol. 2024;16:13–24. doi: 10.2147/JEP.S433524
   PubMedGoogle Scholar
• Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.
   PubMedGoogle Scholar
• Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of a high-fat meal and sprinkled administration on the bioavailability and pharmacokinetics of viloxazine extended-release capsules (Qelbree™) in healthy adult subjects. Eur J Drug Metab Pharmacokinet. 2022;47(1):69–79. doi: 10.1007/s13318-021-00729-6
   PubMed Web of Science ®Google Scholar
• Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155–162. doi: 10.1097/JCP.0000000000001361
   PubMed Web of Science ®Google Scholar
• Nasser A, Gomeni R, Wang Z, et al. Population pharmacokinetics of viloxazine extended-release capsules in pediatric subjects with attention deficit/hyperactivity disorder. J Clin Pharmacol. 2021;61(12):1626–1637. doi: 10.1002/jcph.1940
   PubMed Web of Science ®Google Scholar
• Pisani F, Fazio A, Spina E, et al. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacol (Berl). 1986;90(3):295–298. doi: 10.1007/BF00179180
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Akuly HA, Wagner JH, et al. Viloxazine in the treatment of attention deficit hyperactivity disorder. Front Psychiatry. 2021;12:789982. doi: 10.3389/fpsyt.2021.789982
   PubMed Web of Science ®Google Scholar
• Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285–1300. doi: 10.1080/00498254.2020.1767319
   PubMed Web of Science ®Google Scholar
• Case DE, Reeves PR. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans. Xenobiotica. 1975;5(2):113–129. doi:10.3109/00498257509056097
   PubMed Web of Science ®Google Scholar
• Martinez C, Dominiak P, Kees F, et al. Inhibition of monoamine oxidase by viloxazine in rats. Arzneimittelforschung. 1986;36(5):800–803.
   PubMed Web of Science ®Google Scholar
• Garcia-Olivares J, Yegla B, Zweibaum D, et al. Serotonergic effects of viloxazine measured using 5-HT2 agonist radioligand, [11C]CIMBI-36, in cynomolgus monkeys: a PET imaging approach. Poster presented at: American College of Neuropsychopharmacology Annual Meeting; Dec 4-7, 2022; Phoenix, AZ.
   Google Scholar
• Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–358. doi: 10.1177/1087054719836159
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–380. doi: 10.1097/JCP.0000000000001404
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64. doi: 10.1016/j.clinthera.2021.01.027
   PubMedGoogle Scholar
• Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36(8):897–915. doi: 10.1007/s40263-022-00938-w
   PubMed Web of Science ®Google Scholar
• Open-label study to evaluate long-term safety and efficacy of SPN-812 extended release (ER). ClinicalTrials.Gov identifier: NCT02736656. [updated 2023 Apr 14; cited 2023 Nov 7]. Available from: https://clinicaltrials.gov/study/NCT02736656
   Google Scholar
• Evaluation of SPN-812 (viloxazine extended-release capsule) in adults with ADHD. ClinicalTrials.gov identifier: NCT04016779. [updated 2022 Jul 12. cited 2023 Nov 7]. Available from: https://clinicaltrials.gov/study/NCT04016779
   Google Scholar
• Ramtekkar UP, Reiersen AM, Todorov AA, et al. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49(3):217–228. doi: 10.1016/j.jaac.2009.11.011
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale—5 for children and adolescents: checklists, norms, and clinical interpretation. NY City (NY): The Guilford Press; 2016.
   Google Scholar
• Nasser A, Gomeni R, Wang Z, et al. The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder. Br J Clin Pharmacol. 2022;88(11):4828–4838. doi: 10.1111/bcp.15412
   PubMed Web of Science ®Google Scholar
• Faraone SV, Gomeni R, Hull JT, et al. Executive function outcome of treatment with viloxazine extended-release capsules in children and adolescents with attention-deficit/hyperactivity disorder: a post-hoc analysis of four randomized clinical trials. Paediatr Drugs. 2021;23(6):583–589. doi: 10.1007/s40272-021-00470-2
   PubMed Web of Science ®Google Scholar
• Nasser A, Hull JT, Liranso T, et al. The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials. Neuropsychiatr Dis Treat. 2021;17:1751–1762. doi: 10.2147/NDT.S312011
   PubMed Web of Science ®Google Scholar
• Faraone SV, Gomeni R, Hull JT, et al. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2023;32(3):491–499. doi: 10.1007/s00787-021-01877-5
   PubMed Web of Science ®Google Scholar
• Faraone SV, Gomeni R, Hull JT, et al. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree®): a post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder. Brain Behav. 2023;13(4):e2910. doi: 10.1002/brb3.2910
   PubMed Web of Science ®Google Scholar
• Nasser A, Kosheleff AR, Hull JT, et al. Translating attention-deficit/Hyperactivity disorder rating scale-5 and Weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31(3):214–226. doi: 10.1089/cap.2020.0148
   PubMed Web of Science ®Google Scholar
• Faraone SV, Gomeni R, Hull JT, et al. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 2021;296:113664. doi: 10.1016/j.psychres.2020.113664
   PubMed Web of Science ®Google Scholar
• Nasser A, Kosheleff AR, Hull JT, et al. Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder. Int J Clin Pract. 2021;75(8):e14330. doi: 10.1111/ijcp.14330
   PubMed Web of Science ®Google Scholar
• Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419. doi: 10.1111/j.1600-0447.2008.01194.x
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411. doi: 10.1111/ijcp.12142
   PubMed Web of Science ®Google Scholar
• Nasser A, Hull JT, Earnest J, et al. Effects of viloxazine ER (Qelbree®) on weight and height trajectories: interim results from a long-term, open-label extension trial in pediatric ADHD. CNS Spectr. 2023;28(2):218. doi: 10.1017/S1092852923001323.
   Web of Science ®Google Scholar
• Nasser A, Faison SL, Liranso T, et al. Evaluation of the effect of SPN-812 (viloxazine extended-release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):20m13395. doi: 10.4088/JCP.20m13395
   PubMed Web of Science ®Google Scholar
• Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023;37(7):655–660. doi: 10.1007/s40263-023-01023-6
   PubMed Web of Science ®Google Scholar
• Pliszka S, Issues AWGo Q. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. doi: 10.1097/chi.0b013e318054e724
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477–492. doi: 10.1007/s00787-012-0286-5
   PubMed Web of Science ®Google Scholar
• Medicine BMC. Balancing access to ADHD medication. BMC Med. 2023;21(1):217.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Schulenberg JE, Wilens TE, et al. Prescription stimulant medical and nonmedical use among US secondary school students, 2005 to 2020. JAMA Netw Open. 2023;6(4):e238707. doi: 10.1001/jamanetworkopen.2023.8707
   PubMed Web of Science ®Google Scholar
• Bahn GH, Seo K. Combined medication with stimulants and non-stimulants for attention-deficit/hyperactivity disorder. Clin Psychopharmacol Neurosci. 2021;19(4):705–711. doi: 10.9758/cpn.2021.19.4.705
   PubMed Web of Science ®Google Scholar
• Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52–68. doi: 10.1016/j.neuint.2015.02.001
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–367. doi: 10.1016/j.jaac.2012.01.008
   PubMed Web of Science ®Google Scholar